Classes
DEA Class; Rx
Common Brand Names; Kerlone (DSC), Betoptic, Betoptic S
- Beta-Blockers, Beta-1 Selective
- Antiglaucoma, Beta-Blockers
Description
Beta-1-selective adrenergic antagonist; oral and ophthalmic forms available; does not have ISA or membrane-stabilizing activity; selectivity for the beta-1-receptor makes it a preferred agent in patients with bronchospastic pulmonary disease; used for hypertension and glaucoma.
Indications
Indicated for the treatment of hypertension.
NOTE: Beta-blockers are generally less effective in the treatment of angle-closure glaucoma than for open angle-glaucoma.
Contraindications
Sinus bradycardia, 2°/3° heart block, cardiogenic shock, overt cardiac failure, hypersensitivity, sick sinus syndrome without permanent pacemaker
Adverse Effects
- Fatigue (2-10%)
- Bradycardia (6-8%)
- Chest pain (2-7%)
- Dyspepsia (2-5%)
- Lethargy (3%)
- Cold extremeties (2%)
- Diarrhea (2%)
- Dyspnea (2%)
- Edema (2%)
- Palpitation (2%)
- Pharyngitis (2%)
- Angina
- Arrhythmia
- Flushing
- Depression
- Fever
- Hallucinations
- Malaise
- Neuropathy
- Rash
- Diabetes
- Hyperglycemia
- Anemia
- Hypercholesterolemia
- Hyperlipidemia
- Leukocytosis
- cataracts
Warnings
Bronchospastic disease, cerebrovascular insufficiency, CHF, cardiomegaly, DM, hyperthyroidism/thyrotoxicosis, liver disease, renal impairment, peripheral vascular disease (potential risk of reduced placental perfusion, fetal bradycardia, hypoglycemia), use in pheochromocytoma, IDDM
Surgery/Anesthesia: Chronically administered beta-blockers should not be routinely withdrawn prior to major surgery; however, impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures
Pregnancy and Lactation
Pregnancy Category: C
Lactation: excreted in milk; use caution
Maximum Dosage
20 mg/day PO; 4 drops/day 0.5% ophthalmic solution or 2 drops/day 0.25% ophthalmic suspension in each affected eye.
20 mg/day PO; 4 drops/day 0.5% ophthalmic solution or 2 drops/day 0.25% ophthalmic suspension in each affected eye.
Safety and efficacy of oral and 0.5% ophthalmic solution have not been established; 2 drops/day 0.25% ophthalmic suspension in each affected eye.
Safety and efficacy of oral and 0.5% ophthalmic solution have not been established; 2 drops/day 0.25% ophthalmic suspension in each affected eye.
How supplied
Betaxolol hydrochloride
tablet
- 10mg
- 20mg
ophthalmic solution
- 0.5% (Betoptic)
ophthalmic suspension
- 0.25% (Betoptic S)